论文部分内容阅读
目的探讨Ⅲ期非小细胞肺癌应用同步放化疗综合治疗临床疗效。方法回顾分析本科2004年1月至2007年12月运用综合治疗Ⅲ期非小细胞肺癌28例患者的临床资料。结果放疗结束后,CR、PR、SD、PD率分别为11%,68%,13%,10%。本组16例患者接受2~4个周期后续巩固化疗,余未接受巩固化疔。本组患者1、2、3年生存率分别为61%,34%、16%。本组不良反映较轻,患者可以耐受。结论同步放化疗治疗局部晚期非小细胞肺癌具有较好的疗效,不良反应可耐受,治疗失败原因主要为远处转移。
Objective To investigate the clinical efficacy of concurrent chemoradiation in the treatment of stage Ⅲ non-small cell lung cancer. Methods The clinical data of 28 patients with stage Ⅲ non-small cell lung cancer undergoing comprehensive treatment from January 2004 to December 2007 were retrospectively analyzed. Results After radiotherapy, the rates of CR, PR, SD and PD were 11%, 68%, 13% and 10% respectively. The group of 16 patients received 2 to 4 cycles of follow-up consolidation chemotherapy, I did not receive consolidation 疔. The 1, 2, 3-year survival rates were 61%, 34%, 16% respectively. This group of adverse reactions to light, patients can tolerate. Conclusions Simultaneous chemoradiation and chemotherapy are effective in treating locally advanced non-small cell lung cancer. The adverse reactions are tolerable. The main causes of failure are distant metastasis.